Held by 1 specialist biotech fund
Position history (shares)
Signal Note: Deerfield Exit from Organon (OGN)
Deerfield's exit of its 16.4K share position (~$175K) from the spun-out women's health and legacy pharma portfolio suggests deteriorating conviction in OGN's pipeline execution or commercial trajectory post-Viatris separation (2021). This carries modest signal weight given the small position size, though it warrants monitoring if other specialist healthcare funds follow suit—Organon's pipeline relies heavily on later-stage assets (enobosarm for muscle wasting, relugolix combinations) where clinical or regulatory setbacks could trigger cascading exits.
2 quarters